Cochrane Abstracts
Immune checkpoint inhibitors and chemotherapy versus chemotherapy for early triple‐negative breast cancer
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Immune Checkpoint Inhibitors and Chemotherapy Versus Chemotherapy for Early Triple‐negative Breast Cancer." Cochrane Abstracts, John Wiley & Sons, Inc, 2025. Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/439246/all/Immune_checkpoint_inhibitors_and_chemotherapy_versus_chemotherapy_for_early_triple‐negative_breast_cancer.
Immune checkpoint inhibitors and chemotherapy versus chemotherapy for early triple‐negative breast cancer. Cochrane Abstracts. John Wiley & Sons, Inc; 2025. https://evidence.unboundmedicine.com/evidence/view/Cochrane/439246/all/Immune_checkpoint_inhibitors_and_chemotherapy_versus_chemotherapy_for_early_triple‐negative_breast_cancer. Accessed March 24, 2025.
Immune checkpoint inhibitors and chemotherapy versus chemotherapy for early triple‐negative breast cancer. (2025). In Cochrane Abstracts. John Wiley & Sons, Inc. https://evidence.unboundmedicine.com/evidence/view/Cochrane/439246/all/Immune_checkpoint_inhibitors_and_chemotherapy_versus_chemotherapy_for_early_triple‐negative_breast_cancer
Immune Checkpoint Inhibitors and Chemotherapy Versus Chemotherapy for Early Triple‐negative Breast Cancer [Internet]. In: Cochrane Abstracts. John Wiley & Sons, Inc; 2025. [cited 2025 March 24]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/439246/all/Immune_checkpoint_inhibitors_and_chemotherapy_versus_chemotherapy_for_early_triple‐negative_breast_cancer.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Immune checkpoint inhibitors and chemotherapy versus chemotherapy for early triple‐negative breast cancer
ID - 439246
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/439246/all/Immune_checkpoint_inhibitors_and_chemotherapy_versus_chemotherapy_for_early_triple‐negative_breast_cancer
PB - John Wiley & Sons, Inc
DB - Evidence Central
DP - Unbound Medicine
ER -
